INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC

James Rogers; Alvina Acquaye; Ukeme Ikiddeh-Barnes; Kaitlyn Benson; Lisa Boris; Funto Akindona; Stephen Frederico; Varna Jammula; Yeonju Kim; Michael Timmer; Orwa Aboud; Nicholas Avgeropoulos; Eric Burton; David Cachia; Kevin Camphausen; Howard Colman; Karan Dixit; Jan Drappatz; Erin Dunbar; Peter Forsyth; Edina Komlodi-Pasztor; Jacob Mandel; Eudocia Quant Lee; Surabhi Ranjan; Rimas Lukas; Michael Salacz; Matthew Smith-Cohn; James Snyder; Joseph Wooley; Huma Chaudhry; Brett Theeler; Christina Tsien; James Smirniotopoulos; John Butman; Prashant Chittiboina; John Heiss; Kareem Zaghloul; Kayla O’Donnell; Martha Quezado; Kenneth Aldape; Margarita Raygada; Terri Armstrong; Mark Gilbert; Marta Penas-Prado

doi:10.1093/neuonc/noab196.438

INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC

James Rogers, Alvina Acquaye, Ukeme Ikiddeh-Barnes, Kaitlyn Benson, Lisa Boris, Funto Akindona, Stephen Frederico, Varna Jammula, Yeonju Kim, Michael Timmer, Orwa Aboud, Nicholas Avgeropoulos, Eric Burton, David Cachia, Kevin Camphausen, Howard Colman, Karan Dixit, Jan Drappatz, Erin Dunbar, Peter ForsythEdina Komlodi-Pasztor, Jacob Mandel, Eudocia Quant Lee, Surabhi Ranjan, Rimas Lukas, Michael Salacz, Matthew Smith-Cohn, James Snyder, Joseph Wooley, Huma Chaudhry, Brett Theeler, Christina Tsien, James Smirniotopoulos, John Butman, Prashant Chittiboina, John Heiss, Kareem Zaghloul, Kayla O’Donnell, Martha Quezado, Kenneth Aldape, Margarita Raygada, Terri Armstrong, Mark Gilbert, Marta Penas-Prado

Neurology

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The American Academy of Neurology Institute and Society for Neuro-Oncology recommend multidisciplinary tumor board (MTB) meetings as a quality metric in neuro-oncology. With the COVID-19 pandemic resulting in travel restrictions, we expanded our existing MTB by transitioning to a virtual format that maintained our commitment to providing consultation for primary CNS tumor cases. This transition permitted participation by neuro-oncology teams from over 30 Brain Tumor Trials Collaborative (BTTC)/National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) centers across the United States. Here, we describe results from opening our MTB remotely to these teams. METHODS: We retrospectively reviewed records from remote MTB meetings held between April 2020 and March 2021. To gauge the impact of our MTB on clinical management, we administered a brief survey querying BTTC members. RESULTS: Twenty-eight providers presented 41 cases during 24 virtual MTB meetings (range: 1-4 cases per meeting). Two cases (5%) were presented only for educational value. Approximately half (54%) of the cases discussed dealt with diagnosis/management of an NCI-CONNECT rare CNS tumor. During MTB discussions of the 39 cases seeking diagnosis/management recommendations, 32% received clinical trial recommendations, 10% were suggested to enroll in the NCI Neuro-Oncology Branch (NOB) Natural History Study (NCT02851706), 17% received a recommendation to obtain central neuropathology review, and 100% received recommendations for further disease management. Most BTTC survey respondents (83%) found these recommendations impactful in the management/treatment of their presented case or generally useful/ informative for their clinical practice. CONCLUSION: We describe the feasibility and utility of an innovative virtual multi-institutional MTB. These novel remote meetings allowed for discussion of complex neuro-oncology cases and recommendations from experts, particularly important for those with rare CNS tumors. Our study's findings during the COVID-19 pandemic of the value of providing remote access to MTBs should apply postpandemic.

Original language	American English
Pages (from-to)	vi111-vi111
Journal	Neuro-Oncology
Volume	23
Issue number	Supplement_6
DOIs	https://doi.org/10.1093/neuonc/noab196.438
State	Published - Dec 2021

Access to Document

10.1093/neuonc/noab196.438

Cite this

Rogers, J., Acquaye, A., Ikiddeh-Barnes, U., Benson, K., Boris, L., Akindona, F., Frederico, S., Jammula, V., Kim, Y., Timmer, M., Aboud, O., Avgeropoulos, N., Burton, E., Cachia, D., Camphausen, K., Colman, H., Dixit, K., Drappatz, J., Dunbar, E., ... Penas-Prado, M. (2021). INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC. Neuro-Oncology, 23(Supplement_6), vi111-vi111. https://doi.org/10.1093/neuonc/noab196.438

@article{2889e60b70df4435b6c5b1c2e9fc1628,

title = "INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC",

abstract = "BACKGROUND: The American Academy of Neurology Institute and Society for Neuro-Oncology recommend multidisciplinary tumor board (MTB) meetings as a quality metric in neuro-oncology. With the COVID-19 pandemic resulting in travel restrictions, we expanded our existing MTB by transitioning to a virtual format that maintained our commitment to providing consultation for primary CNS tumor cases. This transition permitted participation by neuro-oncology teams from over 30 Brain Tumor Trials Collaborative (BTTC)/National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) centers across the United States. Here, we describe results from opening our MTB remotely to these teams. METHODS: We retrospectively reviewed records from remote MTB meetings held between April 2020 and March 2021. To gauge the impact of our MTB on clinical management, we administered a brief survey querying BTTC members. RESULTS: Twenty-eight providers presented 41 cases during 24 virtual MTB meetings (range: 1-4 cases per meeting). Two cases (5%) were presented only for educational value. Approximately half (54%) of the cases discussed dealt with diagnosis/management of an NCI-CONNECT rare CNS tumor. During MTB discussions of the 39 cases seeking diagnosis/management recommendations, 32% received clinical trial recommendations, 10% were suggested to enroll in the NCI Neuro-Oncology Branch (NOB) Natural History Study (NCT02851706), 17% received a recommendation to obtain central neuropathology review, and 100% received recommendations for further disease management. Most BTTC survey respondents (83%) found these recommendations impactful in the management/treatment of their presented case or generally useful/ informative for their clinical practice. CONCLUSION: We describe the feasibility and utility of an innovative virtual multi-institutional MTB. These novel remote meetings allowed for discussion of complex neuro-oncology cases and recommendations from experts, particularly important for those with rare CNS tumors. Our study's findings during the COVID-19 pandemic of the value of providing remote access to MTBs should apply postpandemic.",

author = "James Rogers and Alvina Acquaye and Ukeme Ikiddeh-Barnes and Kaitlyn Benson and Lisa Boris and Funto Akindona and Stephen Frederico and Varna Jammula and Yeonju Kim and Michael Timmer and Orwa Aboud and Nicholas Avgeropoulos and Eric Burton and David Cachia and Kevin Camphausen and Howard Colman and Karan Dixit and Jan Drappatz and Erin Dunbar and Peter Forsyth and Edina Komlodi-Pasztor and Jacob Mandel and Lee, {Eudocia Quant} and Surabhi Ranjan and Rimas Lukas and Michael Salacz and Matthew Smith-Cohn and James Snyder and Joseph Wooley and Huma Chaudhry and Brett Theeler and Christina Tsien and James Smirniotopoulos and John Butman and Prashant Chittiboina and John Heiss and Kareem Zaghloul and Kayla O{\textquoteright}Donnell and Martha Quezado and Kenneth Aldape and Margarita Raygada and Terri Armstrong and Mark Gilbert and Marta Penas-Prado",

year = "2021",

month = dec,

doi = "10.1093/neuonc/noab196.438",

language = "American English",

volume = "23",

pages = "vi111--vi111",

journal = "Neuro-Oncology",

issn = "1522-8517",

number = "Supplement_6",

}

Rogers, J, Acquaye, A, Ikiddeh-Barnes, U, Benson, K, Boris, L, Akindona, F, Frederico, S, Jammula, V, Kim, Y, Timmer, M, Aboud, O, Avgeropoulos, N, Burton, E, Cachia, D, Camphausen, K, Colman, H, Dixit, K, Drappatz, J, Dunbar, E, Forsyth, P, Komlodi-Pasztor, E, Mandel, J, Lee, EQ, Ranjan, S, Lukas, R, Salacz, M, Smith-Cohn, M, Snyder, J, Wooley, J, Chaudhry, H, Theeler, B, Tsien, C, Smirniotopoulos, J, Butman, J, Chittiboina, P, Heiss, J, Zaghloul, K, O’Donnell, K, Quezado, M, Aldape, K, Raygada, M, Armstrong, T, Gilbert, M & Penas-Prado, M 2021, 'INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC', Neuro-Oncology, vol. 23, no. Supplement_6, pp. vi111-vi111. https://doi.org/10.1093/neuonc/noab196.438

TY - JOUR

T1 - INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC

AU - Rogers, James

AU - Acquaye, Alvina

AU - Ikiddeh-Barnes, Ukeme

AU - Benson, Kaitlyn

AU - Boris, Lisa

AU - Akindona, Funto

AU - Frederico, Stephen

AU - Jammula, Varna

AU - Kim, Yeonju

AU - Timmer, Michael

AU - Aboud, Orwa

AU - Avgeropoulos, Nicholas

AU - Burton, Eric

AU - Cachia, David

AU - Camphausen, Kevin

AU - Colman, Howard

AU - Dixit, Karan

AU - Drappatz, Jan

AU - Dunbar, Erin

AU - Forsyth, Peter

AU - Komlodi-Pasztor, Edina

AU - Mandel, Jacob

AU - Lee, Eudocia Quant

AU - Ranjan, Surabhi

AU - Lukas, Rimas

AU - Salacz, Michael

AU - Smith-Cohn, Matthew

AU - Snyder, James

AU - Wooley, Joseph

AU - Chaudhry, Huma

AU - Theeler, Brett

AU - Tsien, Christina

AU - Smirniotopoulos, James

AU - Butman, John

AU - Chittiboina, Prashant

AU - Heiss, John

AU - Zaghloul, Kareem

AU - O’Donnell, Kayla

AU - Quezado, Martha

AU - Aldape, Kenneth

AU - Raygada, Margarita

AU - Armstrong, Terri

AU - Gilbert, Mark

AU - Penas-Prado, Marta

PY - 2021/12

Y1 - 2021/12

N2 - BACKGROUND: The American Academy of Neurology Institute and Society for Neuro-Oncology recommend multidisciplinary tumor board (MTB) meetings as a quality metric in neuro-oncology. With the COVID-19 pandemic resulting in travel restrictions, we expanded our existing MTB by transitioning to a virtual format that maintained our commitment to providing consultation for primary CNS tumor cases. This transition permitted participation by neuro-oncology teams from over 30 Brain Tumor Trials Collaborative (BTTC)/National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) centers across the United States. Here, we describe results from opening our MTB remotely to these teams. METHODS: We retrospectively reviewed records from remote MTB meetings held between April 2020 and March 2021. To gauge the impact of our MTB on clinical management, we administered a brief survey querying BTTC members. RESULTS: Twenty-eight providers presented 41 cases during 24 virtual MTB meetings (range: 1-4 cases per meeting). Two cases (5%) were presented only for educational value. Approximately half (54%) of the cases discussed dealt with diagnosis/management of an NCI-CONNECT rare CNS tumor. During MTB discussions of the 39 cases seeking diagnosis/management recommendations, 32% received clinical trial recommendations, 10% were suggested to enroll in the NCI Neuro-Oncology Branch (NOB) Natural History Study (NCT02851706), 17% received a recommendation to obtain central neuropathology review, and 100% received recommendations for further disease management. Most BTTC survey respondents (83%) found these recommendations impactful in the management/treatment of their presented case or generally useful/ informative for their clinical practice. CONCLUSION: We describe the feasibility and utility of an innovative virtual multi-institutional MTB. These novel remote meetings allowed for discussion of complex neuro-oncology cases and recommendations from experts, particularly important for those with rare CNS tumors. Our study's findings during the COVID-19 pandemic of the value of providing remote access to MTBs should apply postpandemic.

AB - BACKGROUND: The American Academy of Neurology Institute and Society for Neuro-Oncology recommend multidisciplinary tumor board (MTB) meetings as a quality metric in neuro-oncology. With the COVID-19 pandemic resulting in travel restrictions, we expanded our existing MTB by transitioning to a virtual format that maintained our commitment to providing consultation for primary CNS tumor cases. This transition permitted participation by neuro-oncology teams from over 30 Brain Tumor Trials Collaborative (BTTC)/National Cancer Institute-Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) centers across the United States. Here, we describe results from opening our MTB remotely to these teams. METHODS: We retrospectively reviewed records from remote MTB meetings held between April 2020 and March 2021. To gauge the impact of our MTB on clinical management, we administered a brief survey querying BTTC members. RESULTS: Twenty-eight providers presented 41 cases during 24 virtual MTB meetings (range: 1-4 cases per meeting). Two cases (5%) were presented only for educational value. Approximately half (54%) of the cases discussed dealt with diagnosis/management of an NCI-CONNECT rare CNS tumor. During MTB discussions of the 39 cases seeking diagnosis/management recommendations, 32% received clinical trial recommendations, 10% were suggested to enroll in the NCI Neuro-Oncology Branch (NOB) Natural History Study (NCT02851706), 17% received a recommendation to obtain central neuropathology review, and 100% received recommendations for further disease management. Most BTTC survey respondents (83%) found these recommendations impactful in the management/treatment of their presented case or generally useful/ informative for their clinical practice. CONCLUSION: We describe the feasibility and utility of an innovative virtual multi-institutional MTB. These novel remote meetings allowed for discussion of complex neuro-oncology cases and recommendations from experts, particularly important for those with rare CNS tumors. Our study's findings during the COVID-19 pandemic of the value of providing remote access to MTBs should apply postpandemic.

UR - https://www.mendeley.com/catalogue/0293b47f-8b71-3712-b9b1-5c21a009b125/

U2 - 10.1093/neuonc/noab196.438

DO - 10.1093/neuonc/noab196.438

M3 - Article

SN - 1522-8517

VL - 23

SP - vi111-vi111

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - Supplement_6

ER -